Retatrutide appears to be a new pharmaceutical in the fight against obesity. This groundbreaking drug, categorized as a dual GLP-1 and GIP receptor agonist, demonstrates promising results in clinical trials. By boosting these receptors, Retatrutide reduces hunger pangs, {promotesinsulin secretion, and ultimately results in significant reduction in